Talzenna (talazoparib) + Xtandi (enzalutamide) prolongs overall survival in phase III TALAPRO-2 trial for prostate cancer
Pfizer Inc. announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor,… read more.